From Omicron's sequence, there's a lot of antigenic drift, posing the threat of evading our immune response. Good that vaccine companies are gearing up for it. But we ought to be pressing hard for a pan-sarbecovirus vaccine that would target *all* variants businesswire.com/news/home/2021…

A short thread with some thoughts & calculations of mine about Omicron. Still preliminary, so don't take any figures as final, but it's a start... 🧵

First look at Omicron neutralization from Alex Sigal. That is a huge drop.

Anybody who says "I hate Twitter" has never tried to keep up with a pandemic in which crucial new data is released every few hours, data that often requires sophisticated interpretation by domain experts in areas ranging from virology to epidemiology to supply chain to sociology.

Excited to finally share our SARS-CoV-2 paper in nature !! 🙌 Have learnt so much being part of this amazing team AK Reuschl Lorena Zuliani Alvarez, PhD Mehdi Bouhaddou, PhD Towerslab Jolly Lab Krogan Lab 🦠🔬Dr Matthew VX Whelan / Mathúin Ó Faoláin🔬🦠 Ian Goodfellow & many more nature.com/articles/s4158… here’s what we found 👇

Amongst God knows what wave and Omicron - it looks like White Christmas in Copenhagen. Happy holidays to all 🎉⭐️ @ Kongens Lyngby instagram.com/p/CX3efpNIouEm…

T-cell-based vaccines have the potential to elicit a broad and durable immune response to SARS-CoV-2 including Omicron and future variants. Learn more about our collaboration with Nykode Therapeutics on next-gen COVID-19 vaccines at rebrand.ly/4cvq7gc. Agnete B. Fredriksen

Nykode CEO Michael Engsig and CISO Agnete B. Fredriksen present an update on its next-gen COVID-19 vaccine candidates, including a T-cell-based vaccine developed using epitopes identified and validated by our immune medicine platform. Watch now at rebrand.ly/sxi7k8k.

It's very hard to watch today as the US hospitalizations climbed above 150,000, ICUs more than 25,000, and nearly 2,700 deaths—the vast majority were preventable by vaccinations and/or boosters. And >900,000 new cases, some of whom will progress to severe disease or #LongCovid

In week 50 BA.2 was 2% in Denmark. “That number has now risen to 28% in Week 1.” “At the same time, the proportion of cases of BA1 has dropped from 72% to 68%. The last 4% is made up of the delta variant.” Interestingly, Delta hung on in DK in early ‘22 berlingske.dk/danmark/underv…

This is so true. Much work ahead of us. Clear words in this short opinion. COVID-19: endemic doesn’t mean harmless nature.com/articles/d4158…

🤔 Israeli panel recommends fourth Covid vaccine dose for all adults ft.com/content/8fa9fb…

hbr.org/2007/02/in-pra…